Cassava Sciences Inc vs Global X Lithium & Battery Tech ETF — how do they compare? Cassava Sciences Inc trades at $1.1 (market cap $53.14M), while Global X Lithium & Battery Tech ETF trades at $68.85. The key difference: Global X Lithium & Battery Tech ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | LIT | |
|---|---|---|
Market Cap | $53.14M | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $4.64 | $91.62 |
52-Week Low | $1.09 | $39.73 |
Enterprise Value | -$33.43M | — |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Global X Lithium & Battery Tech ETF (LIT) trades at $68.72, down 4.0% over 24 hours amid bearish technical signals. The ETF has demonstrated strong momentum with a 125% return from last year's lows, driven by accelerating EV adoption and lithium market recovery. Recent news highlights expanding global EV sales, China's ambitious 30% NEV fleet target by 2030, and ongoing geopolitical influences on energy markets. Technical indicators show oversold conditions with RSI levels below 30, while moving averages remain bearish.
The outlook for LIT remains tied to lithium demand growth from EVs, energy storage, and semiconductors. Investment opportunities exist in the ongoing electrification trend and supply chain reshoring, while risks include Chinese export controls, potential EV demand volatility, and competitive pressures from Chinese automakers entering global markets.
Trailing returns across standard periods
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →LIT invests in the full lithium cycle, from mining and refining to battery production and EV manufacturing. It tracks the Solactive Global Lithium Index, with top holdings including Rio Tinto, Albemarle, and Tesla, as well as major battery makers like Samsung SDI.
Read more on LIT →